Back to News & Insights

The CMS’s Clinical Super Intelligence Roadmap and the Evolving Federal Regulatory Landscape

On November 13, 2026 the Centers for Medicare & Medicaid Services (CMS) released, A Clinical Super Intelligence Roadmap: Better Answers, Faster Care, and Lower Costs. The document reflects CMS’s view that regulatory efforts related to clinical super intelligence (“SI”) should be guided by principles designed to accelerate responsible adoption while preserving public trust and accountability. It outlines a long-term strategy to integrate clinical SI into care delivery, payment models and regulatory oversight. This comes as CMS has worked over the past year to convene and prompt stakeholders across the health care system to make commitments towards secure, personalized, and interoperable health care technology through its Health Tech Ecosystem. While the document has no binding legal effect or formal proposals, it provides a clear signal of the federal government’s direction on the regulation, oversight, and reimbursement of clinical SI. It is likely that future guidance, rulemaking and announcements may follow as the Administration seeks to implement this roadmap.

Key Takeaways

  • Lifecycle Oversight Rather Than Point in Time Approval: Rather than requiring flawless pre-deployment evidence, CMS endorses a “better than today” standard which clinical SI can be introduced through staged deployment, supported by human oversight, transparent performance reporting, and continuous real-world monitoring.
  • Payment Policy Will Be a Primary Driver of Clinical SI Adoption: CMS intends to use Medicare, Medicaid, and the Centers for Medicare and Medicaid Innovation (CMMI) payment models to accelerate adoption of clinical SI, including expanded outcomes-based reimbursement and integration of SI-enabled care into primary care and total-cost-of-care initiatives.
  • Federal and State Roles in Clinical SI Regulation Remain a Key Unknown: CMS advocates for a more coordinated national approach to avoid a patchwork of state requirements and is exploring partnerships with states through regulatory sandboxes to address jurisdictional questions involving licensure, practice-of-medicine rules, and reimbursement.
  • Providers Should Use Governance to Align With CMS Principles: Organizations deploying clinical SI should establish baseline performance metrics, robust governance frameworks, ongoing monitoring, and clear accountability structures to support reimbursement opportunities, satisfy emerging regulatory requirements, and manage evolving malpractice and operational risks.

“Better than Today” as a Guiding Principle

Acknowledging that the current health care system is imperfect and in need of improvement, CMS argues that clinical SI should be held to a “better than today” standard, measured by its ability to improve safety, effectiveness, access, and patient outcomes. At the same time, CMS makes clear that it will not wait for “flawless evidence to open pathways” to clinical SI, but instead will “require evidence to keep them open.” Reflecting a growing consensus among regulators and policymakers, including ongoing discussions at the FDA regarding lifecycle oversight of SI-enabled technologies, the guidance recognizes that the safety and effectiveness of clinical SI often can be assessed most meaningfully through real-world use. Accordingly, CMS signals that trust in clinical SI cannot be established through a one-time pre-deployment review alone. Rather, trust must be earned through a deliberate, evidence-driven process that allows clinical SI tools to enter clinical practice through staged deployment, with meaningful human oversight, transparent performance reporting, and continuous real-world monitoring to demonstrate safety, effectiveness, and accountability as adoption expands.

Payment Pathways as a Policy Lever

CMS indicated that it would continue to use its oversight of payment pathways as essential tools for accelerating the adoption of clinical SI. The agency intends to prioritize technologies that lower the total cost of care while expanding access and improving outcomes, building on existing value-based payment models. It expects to expand the Advancing Chronic Care with Effective, Scalable Solutions (ACCESS) model to primary care for additional chronic conditions, incorporate SI-enabled solutions into Innovation Center primary care and total-cost-of-care initiatives such as Long-term Enhanced ACO Design (LEAD) and Achieving Healthcare Efficiency through Accountable Design (AHEAD), and explore outcomes-based reimbursement in Original Medicare. CMS also suggests that certain components of the annual wellness visit could be delivered through clinical SI along with expanded coverage of SI-enabled care models in existing payment programs. Across these initiatives, CMS emphasizes that SI-driven care must remain connected to clinicians and health care facilities so patients can be escalated seamlessly when human intervention is needed.

Federal-State Jurisdiction and Regulatory Coordination

The guidance also signals interest in clarifying the boundary between federal and state authority over clinical SI. This boundary has become increasingly murky as states move forward with legislation and policies to regulate SI through the traditional oversight of the practice of medicine while the FDA continues to refine its approach to regulating clinical SI as a regulated medical product. The guidance advances the argument that a national approach to regulating clinical SI is needed to avoid a patchwork of state requirements that is viewed as a barrier to adoption at scale. CMS stated its interest in partnering with states, possibly through SI regulatory sandboxes, to define jurisdictional boundaries for areas such as licensure and the practice of medicine, while also pairing such programs with reimbursement mechanisms to test innovative payment models that support responsible adoption.

What Comes Next for Clinical SI: Policy and Operational Considerations

Providers using clinical SI should prepare now for a “better than today” standard. Before deploying any SI-enabled clinical workflow, governance policies should establish baseline performance measures—such as clinical accuracy, turnaround times, access to care, patient outcomes, and clinician workload—and continue tracking them throughout implementation. These baselines will likely become the benchmark regulators, payers, and litigants use to judge whether SI improved care. Organizations that can show measurable improvements over traditional care models will be best positioned to justify deployment and to participate in outcomes-based reimbursement models.

Mature and robust clinical SI governance policies are therefore a strategic imperative, not just a risk-management tool. An effective program will include documented validation and testing protocols, continuous performance monitoring, clear oversight and accountability structures, and appropriate disclosure and consent processes. These safeguards also satisfy emerging state requirements, such as disclosure obligations for certain uses of artificial intelligence in patient care. Governance will remain a critical mechanism to establish trust, demonstrate responsible use, withstand regulatory scrutiny, and adapt as federal and state policymakers move to regulate this space.

Linking clinical SI to payment incentives will strengthen the business case for adoption, but it will also raise new compliance and liability questions. Deployers should closely monitor how evolving laws and regulations allocate liability as responsibility shifts between clinicians and developers or purchasers of clinical SI tools. Increased scrutiny of physician training, credentialing, clinical supervision, and escalation protocols will make careful negotiation of liability allocation and indemnification provisions in vendor agreements increasingly essential. New compliance obligations, particularly those grounded in the corporate practice of medicine doctrine and its requirement of physician control over care delivery, may emerge and require licensed professionals to serve a more formal oversight role in the deployment of clinical SI.

Expect the themes of the CMS guidance to carry into 2027, shaping broader regulatory discussions while also directly influencing legislative proposals and agency actions. Additional guidance from CMS expanding upon the principles outlined in this roadmap should be expected in the new year. Those comments may arrive alongside FDA’s effort to address the more than 500 comments submitted in response to its August 2026 discussion paper on “Considerations for the Regulation of Generative AI-Enabled Medical Devices.” Taken together, these forthcoming developments may provide a stronger signal that federal regulators are moving toward a lifecycle oversight model that places greater emphasis on post-deployment monitoring and while also clarifying which stakeholders—developers or deployers—will bear certain obligations. At the same time, state legislatures, regulators, and professional licensing bodies will continue to shape deployment through expansion of regulatory sandboxes, consideration of legislative proposals to license clinical SI, and incorporation of guidance from organizations such as the American Medical Association and the Federation of State Medical Boards which seeks to establish standards for accountability and oversight in the deployment and use of clinical SI.


The terminology used in this alert reflects the directive of the Executive Order on Inaugurating the Era of Super Intelligence, which directs federal executive agencies to use the terms “Super Intelligence” and “SI” in place of “Artificial Intelligence” and “AI” in official communications and other non-statutory documents. See Executive Order on Inaugurating the Era of Super Intelligence, § 2(a), 91 Fed. Reg. ___ (Sept. 29, 2026), available at https://www.federalregister.gov/d/2026-20321.